Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / IPOS - PAVmed subsidiary Lucid Diagnostics prices 5M-share IPO at $14

IPOS - PAVmed subsidiary Lucid Diagnostics prices 5M-share IPO at $14

Renaissance Capital Greenwich Fund
Lucid Diagnostics (LUCD), a cancer prevention medical diagnostics company, and subsidiary of PAVmed (NASDAQ:PAVM) has priced its IPO of 5M shares of its common stock at $14.00/share. Expected gross proceeds are $70M. Nasdaq trading kicks off October 14, 2021. Underwriters' over-allotment is an additional 750K shares. Closing date is October 18. Lucid is focused on the treatment for patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test, is the first and only commercially available diagnostic test capable of serving as a screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

For further details see:

PAVmed subsidiary, Lucid Diagnostics prices 5M-share IPO at $14
Stock Information
Company Name: Renaissance Capital Greenwich Fund
Stock Symbol: IPOS
Market: NYSE
Menu
IPOS IPOS Quote IPOS Short IPOS News IPOS Articles IPOS Message Board
Get IPOS Alerts

News, Short Squeeze, Breakout and More Instantly...